Effects of selenium supplementation on glucose homeostasis and free androgen index in women with polycystic ovary syndrome: A randomized, double blinded, placebo controlled clinical trial

Journal of Trace Elements in Medicine and Biology

Volumn 34, Issue , 2016, Pages 56-61

  Mohammad Hosseinzadeh, Fatemeh ^a   Hosseinzadeh Attar, Mohammad Javad ^a   Yekaninejad, Mir Saeed ^b   Rashidi, Batool ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Free androgen index; Insulin resistance; Polycystic ovary syndrome; Selenium; Total testosterone

Indexed keywords

GLUCOSE; INSULIN; PLACEBO; SELENIUM; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; ANDROGEN; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FREE ANDROGEN INDEX; HUMAN; INSULIN RESISTANCE; IRANIAN PEOPLE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; BLOOD; DIETARY SUPPLEMENT; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; METABOLISM; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; ANDROGENS; BLOOD GLUCOSE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HOMEOSTASIS; HUMANS; POLYCYSTIC OVARY SYNDROME; SELENIUM; TESTOSTERONE; YOUNG ADULT;

EID: 84957543771     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2016.01.002     Document Type: Article

References (50)

1. Hart R., Hickey M., Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract. Res. Clin. Obstet. Gynaecol. 2004, 18:671-683.
2. Azziz R., Marin C., Hoq L., Badamgarav E., Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J. Clin. Endocrinol. Metab. 2005, 90:4650-4658.
3. Franks S. Polycystic ovary syndrome. N. Engl. J. Med. 1995, 333:853-861.
4. Moran L.J., Misso M.L., Wild R.A., Norman R.J. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 2010, 16:347-363.
5. Luque-Ramírez M., Escobar-Morreale H.F. Polycystic ovary syndrome as a paradigm for prehypertension, prediabetes, and preobesity. Curr. Hypertens. Rep. 2014, 16:1-10.
6. Steinbrenner H., Sies H. Protection against reactive oxygen species by selenoproteins. Biochim. Biophys. Acta (BBA)-Gen. 2009, 1790:1478-1485.
7. Stranges S., Marshall J.R., Natarajan R., Donahue R.P., Trevisan M., Combs G.F., et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann. Intern. Med. 2007, 147:217-223.
8. Coskun A., Arikan T., Kilinc M., Arikan D.C., Ekerbiçer H.Ç. Plasma selenium levels in Turkish women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013, 168:183-186.
9. Bleys J., Navas-Acien A., Guallar E. Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Arch. Intern. Med. 2008, 168:404-410.
10. Stapleton S. Selenium an insulin mimetic. Cell. Mol. Life Sci. 2000, 57:1874-1879.
11. Li Y.B., Han J.Y., Jiang W., Wang J. Selenium inhibits high glucose-induced cyclooxygenase-2 and P-selectin expression in vascular endothelial cells. Mol. Biol. Rep. 2011, 38:2301-2306.
12. Brigelius-Flohe R., Banning A., Kny M., Bol G.F. Redox events in interleukin-1 signaling. Arch. Biochem. Biophys. 2004, 423:66-73.
13. Chen X., Scholl T.O., Leskiw M.J., Donaldson M.R., Stein T.P. Association of glutathione peroxidase activity with insulin resistance and dietary fat intake during normal pregnancy. J. Clin. Endocrinol. Metab. 2003, 88:5963-5968.
14. Faghihi T., Radfar M., Barmal M., Amini P., Qorbani M., Abdollahi M., et al. A randomized, placebo-controlled trial of selenium supplementation in patients with type 2 diabetes: effects on glucose homeostasis, oxidative stress, and lipid profile. Am. J. Ther. 2014, 21:491-495.
15. Jamilian M., Razavi M., Fakhrie Kashan Z., Ghandi Y., Bagherian T., Asemi Z. Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin. Endocrinol. 2015, 82:885-891.
16. Razavi M., Jamilian M., Kashan Z.F., Heidar Z., Mohseni M., Ghandi Y., et al. Selenium supplementation and the effects on reproductive outcomes, biomarkers of inflammation, and oxidative stress in women with polycystic ovary syndrome. Horm. Metab. Res. 2015, 47:e1-e3.
17. F. BCJM, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome: Rotterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group, Fertility and Sterility 81 (2004) 19-25.
18. Selimoglu H., Duran C., Kiyici S., Ersoy C., Guclu M., Ozkaya G., et al. The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J. Endocrinol. Invest. 2010, 33:234-238.
19. Matthews D., Hosker J., Rudenski A., Naylor B., Treacher D., Turner R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
20. Vanky E., Kjøtrød S., Salvesen K.Å., Romundstad P., Moen M.H., Carlsen S.M. Clinical, biochemical and ultrasonographic characteristics of Scandinavian women with PCOS. Acta Obstet. Gynecol. Scand. 2004, 83:482-486.
21. Safaralizadeh R., Kardar G.A., Pourpak Z., Moin M., Zare A., Teimourian S. Serum concentration of selenium in healthy individuals living in Tehran. Nutr. J. 2005, 4:32.
22. Krinsky N.I., Beecher G.R., Burk R.F., Chan A.C., Erdman J.W., Jacob R.A., et al. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids 2000, The National Academy of Sciences, Washington D.C.
23. Burk R.F., Norsworthy B.K., Hill K.E., Motley A.K., Byrne D.W. Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol. Biomark. Prev. 2006, 15:804-810.
24. Aldosary B.M., Sutter M.E., Schwartz M., Morgan B.W. Case series of selenium toxicity from a nutritional supplement. Clin. Toxicol. 2012, 50:57-64.
25. Czernichow S., Couthouis A., Bertrais S., Vergnaud A.-C., Dauchet L., Galan P., et al. Antioxidant supplementation does not affect fasting plasma glucose in the supplementation with antioxidant vitamins and minerals (SU VI MAX) study in France: association with dietary intake and plasma concentrations. Am. J. Clin. Nutr. 2006, 84:395-399.
26. Algotar A.M., Stratton M.S., Stratton S.P., Hsu C.-H., Ahmann F.R. No effect of selenium supplementation on serum glucose levels in men with prostate cancer. Am. J. Med. 2010, 123:765-768.
27. Lippman S.M., Klein E.A., Goodman P.J., Lucia M.S., Thompson I.M., Ford L.G., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). J. Am. Med. Assoc. 2009, 301:39-51.
28. Stranges S., Galletti F., Farinaro E., D'Elia L., Russo O., Iacone R., et al. Associations of selenium status with cardiometabolic risk factors: an 8-year follow-up analysis of the Olivetti heart study. Atherosclerosis 2011, 217:274-278.
29. Bleys J., Navas-Acien A., Guallar E. Serum selenium and diabetes in US adults. Diabetes Care 2007, 30:829-834.
30. Stranges S., Sieri S., Vinceti M., Grioni S., Guallar E., Laclaustra M., et al. A prospective study of dietary selenium intake and risk of type 2 diabetes. BMC Public Health 2010, 10:564.
31. Wang C., Yang S., Zhang N., Mu Y., Ren H., Wang Y., et al. Long-term supranutritional supplementation with selenate decreases hyperglycemia and promotes fatty liver degeneration by inducing hyperinsulinemia in diabetic db/db mice. PLoS One 2014, 9:e101315.
32. Labunskyy V.M., Lee B.C., Handy D.E., Loscalzo J., Hatfield D.L., Gladyshev V.N. Both maximal expression of selenoproteins and selenoprotein deficiency can promote development of type 2 diabetes-like phenotype in mice. Antioxid. Redox Signaling 2011, 14:2327-2336.
33. Goldstein B.J., Mahadev K., Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 2005, 54:311-321.
34. May J.M., de Haen C. Insulin-stimulated intracellular hydrogen peroxide production in rat epididymal fat cells. J. Biol Chem. 1979, 254:2214-2220.
35. Mahadev K., Motoshima H., Wu X., Ruddy J.M., Arnold R.S., Cheng G., et al. The NAD(P)H oxidase homolog Nox4 modulates insulin-stimulated generation of H2O2 and plays an integral role in insulin signal transduction. Mol. Cell. Biol. 2004, 24:1844-1854.
36. Mahadev K., Zilbering A., Zhu L., Goldstein B.J. Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade. J. Biol. Chem. 2001, 276:21938-21942.
37. Saito Y., Yoshida Y., Akazawa T., Takahashi K., Niki E. Cell death caused by selenium deficiency and protective effect of antioxidants. J. Biol. Chem. 2003, 278:39428-39434.
38. Steinbrenner H., Alili L., Bilgic E., Sies H., Brenneisen P. Involvement of selenoprotein P in protection of human astrocytes from oxidative damage. Free Radic. Biol. Med. 2006, 40:1513-1523.
39. Steinbrenner H., Bilgic E., Alili L., Sies H., Brenneisen P. Selenoprotein P protects endothelial cells from oxidative damage by stimulation of glutathione peroxidase expression and activity. Free Radic. Res. 2006, 40:936-943.
40. Brigelius-Flohe R. Tissue-specific functions of individual glutathione peroxidases. Free Radic. Biol. Med. 1999, 27:951-965.
41. Steinbrenner H. Interference of selenium and selenoproteins with the insulin-regulated carbohydrate and lipid metabolism. Free Radic. Biol. Med. 2013, 65:1538-1547.
42. Hurst R., Armah C.N., Dainty J.R., Hart D.J., Teucher B., Goldson A.J., et al. Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial. Am. J. Clin. Nutr. 2010, 91:923-931.
43. Xia Y., Hill K.E., Li P., Xu J., Zhou D., Motley A.K., et al. Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: a placebo-controlled, double-blind study of selenomethionine supplementation in selenium-deficient Chinese subjects. Am. J. Clin. Nutr. 2010, 92:525-531.
44. Misu H., Takamura T., Takayama H., Hayashi H., Matsuzawa-Nagata N., Kurita S., et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010, 12:483-495.
45. Yang S., Hwang S., Choi H., Yoo H., Seo J., Kim S., et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J.Clin. Endocrinol. Metab. 2011, 96:E1325-E1329.
46. Roman M., Lapolla A., Jitaru P., Sechi A., Cosma C., Cozzi G., et al. Plasma selenoproteins concentrations in type 2 diabetes mellitus-a pilot study. Transl. Res. 2010, 156:242-250.
47. Nouarie M., Pourshams A., Kamangar F., Sotoudeh M., Derakhshan M.H., Akbari M.R., et al. Ecologic study of serum selenium and upper gastrointestinal cancers in Iran. World J. Gastroenterol. 2004, 10:2544-2546.
48. Poretsky L., Cataldo N.A., Rosenwaks Z., Giudice L.C. The insulin-related ovarian regulatory system in health and disease. Endocr. Rev. 1999, 20:535-582.
49. Pugeat M., Crave J.C., Elmidani M., Nicolas M.H., Garoscio-Cholet M., Lejeune H., et al. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J. Steroid Biochem. Mol. Biol. 1991, 40:841-849.
50. Gutt M., Davis C.L., Spitzer S.B., Llabre M.M., Kumar M., Czarnecki E.M., et al. Validation of the insulin sensitivity index (ISI 0, 120): comparison with other measures. Diabetes Res. Clin. Pract. 2000, 47:177-184.